- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03291418
To Compare the Gastrointestinal Safety of a 14-Day Oral Dosing Regimen of ATB-346 to Sodium Naproxen in Healthy Subjects
A Double-Blind, Controlled Study to Compare the Gastrointestinal Safety of a 14-Day Oral Dosing Regimen of ATB-346 to Sodium Naproxen in Healthy Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M9C 4Z5
- Topstone Clinical Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
1. Adult subjects ≥18 to ≤65 years of age 2. Healthy subject with no history of significant gastrointestinal (GI) disease, arthritis or bleeding disorders 3. Subject with laboratory values within normal and acceptable ranges or out of range laboratory values deemed non-clinically significant, as per investigator discretion 4. BMI ≤35 kg/m2 5. Non-smoker for >1 month prior to screening 6. Subject able and willing to give written informed consent, and understand and adhere to protocol requirements 7. Female of childbearing potential using adequate birth control for at least 28 days prior to the first dose of the study drug and for 60 days after the last drug administration, as specified in one of the options below:
- Abstinence from heterosexual intercourse
- Contraception to include birth control pills, injectable/implant/transdermal patch
- Intrauterine device
- Cervical cap or diaphragm with use of spermicide
Condom with spermicide Male subjects with female partners of childbearing potential must agree to abstain from sexual intercourse or use on the above forms of contraception for a period of 3 months following the last drug administration.
8. Female of non-childbearing potential who is either sterile (via complete hysterectomy, bilateral oophorectomy, or tubal ligation) or in a menopausal state for at least one year 9. Subject who consumes no more than 1 alcoholic serving/drink per day (e.g. 355 mL (12 fluid (fl) ounces (oz)) of regular beer; 148 mL (5 fl oz) of wine; 45 mL (1.5 fl oz) of distilled spirits) 10. Subject willing to refrain from alcohol consumption for 48 hours prior to the screening endoscopy and randomization, and 48 hours prior to the Day 14 endoscopy.
11. Screening endoscopy is free from any observable gastroduodenal erosions or ulcers, and no greater than 10 mucosal petechiae.
Exclusion Criteria:
1. Subject with abnormal baseline laboratory values deemed to be clinically significant by the Investigator 2. Ongoing use of any prescription or over-the-counter medications, or natural/herbal or vitamin preparations, that in the opinion of the Investigator would interfere with the study objectives, or impact subject safety (with the exception of systemic contraceptives and hormone replacement therapy) 3. Use of investigational drugs up to thirty (30) days before screening 4. Use of the following medications within two weeks prior to randomization:
- NSAIDs, Aspirin, aspirin-containing products or naproxen-containing medications, NSAID-containing products
- Proton pump inhibitors
- H-2 blockers
- Anti-platelet agents
- Anti-coagulants
- Antimicrobials
Other gastroprotective agents such as antacids, misoprostol, or bismuth-containing products 5. Subject-reported past history of gastrointestinal ulcer or gastrointestinal bleeding, or any clinically significant gastrointestinal disease.
6. Positive for Helicobacter pylori urea breath test at the screening visit 7. Clinically significant gastrointestinal, hepatic or renal disease, or any other conditions known to significantly impact or interfere with absorption, distribution, metabolism or elimination of the investigational drug(s) 8. Clinically significant past or present diseases or illnesses that, in the opinion of the investigator, would interfere with the study objectives or integrity or with the subject's safety.
9. Subject with seated pulse rates <50 beats per minute (bpm) or >100 bpm at screening 10. Seated blood pressure <100/60 mm Hg or >140/90 mm Hg at screening 11. Known hypersensitivities to naproxen, other non-steroidal anti-inflammatory (NSAID) agents, related products (including excipients and formulations) 12. Known hypersensitivities to drugs used for sedation during endoscopy 13. Severe hypersensitivity (including angioedema) to any drugs 14. Use of medications with known drug-drug interactions including potent enzyme-modifying drugs, potent inhibitors and/or inducers of CYP enzymes (such as fluoxetine, barbiturates or St. John's Wort) in the previous thirty (30) days before randomization 15. Female who is pregnant or breastfeeding 16. Positive test for HIV antigen/antibody combination, hepatitis B surface antigen (HBsAg), or anti-Hepatitis C virus tests 17. Positive urine drug test at screening 18. Positive urine alcohol test prior to the screening endoscopy 19. Any clinically significant illness up to thirty (30) days before screening
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ATB-346 OR Placebo
Intervention: Drug: ATB-346 dosed orally at 250 mg once daily for 14 days Intervention: Drug: Placebo (for ATB-346) dosed once daily for 14 days
|
Comparison of gastrointestinal effects
|
Active Comparator: Naproxen sodium
Intervention: Drug: naproxen sodium dosed orally at 550 mg twice daily for 14 days
|
Comparison of gastrointestinal effects
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Gastroduodenal ulcers >=3mm diameter
Time Frame: At completion of 14 days of oral dosing
|
Incidence of gastric or duodenal ulcers of at least 3 mm diameter with unequivocal depth
|
At completion of 14 days of oral dosing
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Gastroduodenal ulcers >=5mm diameter
Time Frame: At completion of 14 days of oral dosing
|
Incidence of gastric or duodenal ulcers of at least 5 mm diameter with unequivocal depth
|
At completion of 14 days of oral dosing
|
gastroduodenal erosions
Time Frame: At completion of 14 days of oral dosing
|
Number of gastric and/or duodenal erosions and/or ulcers
|
At completion of 14 days of oral dosing
|
Dyspepsia
Time Frame: At completion of 14 days of oral dosing
|
Incidence of dyspepsia leading to study withdrawal
|
At completion of 14 days of oral dosing
|
Hematocrit
Time Frame: At completion of 14 days of oral dosing
|
Change from baseline in hematocrit levels
|
At completion of 14 days of oral dosing
|
Thromboxane B2 levels
Time Frame: At completion of 14 days of oral dosing
|
Changes from baseline in ex vivo whole blood thromboxane B2 (TXB2) synthesis
|
At completion of 14 days of oral dosing
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Deepen Patel, MD, Topstone Clinical Research
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Gastrointestinal Diseases
- Stomach Diseases
- Intestinal Diseases
- Peptic Ulcer
- Duodenal Diseases
- Stomach Ulcer
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Gout Suppressants
- Naproxen
Other Study ID Numbers
- ATB-346-P2GIS
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric Ulcer
-
Changhai HospitalPeking Union Medical College Hospital; Chinese PLA General Hospital; RenJi Hospital and other collaboratorsCompletedChronic Gastritis | Gastric Diseases, | Gastric Ulcer, | Gastric Polyps, | Early Gastric Cancer,China
-
TakedaCompletedGastric Ulcer, Duodenal Ulcer, Acute Stress Gastritis, and Acute Gastric Mucosal Lesions
-
The Catholic University of KoreaSt Vincent's Hospital; Bucheon St. Mary's HospitalUnknown
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownBleeding Gastric Ulcer | Bleeding Duodenal UlcerChina
-
TakedaCompleted
-
TakedaCompletedGastric Ulcers | Duodenal UlcersJapan
-
TakedaCompletedGastric Ulcers | Duodenal UlcersJapan
-
TakedaCompletedGastric Ulcers | Duodenal UlcersJapan
-
Chuncheon Sacred Heart HospitalCompletedGastric Ulcer Associated With Helicobacter PyloriKorea, Republic of
-
Nanfang Hospital of Southern Medical UniversityUnknown
Clinical Trials on ATB-346 OR Placebo
-
Antibe Therapeutics Inc.Algorithme Pharma IncCompleted
-
Antibe Therapeutics Inc.Veristat, Inc.Completed
-
AutotelicbioRecruitingDiabetes Mellitus, Type 2 | Essential HypertensionKorea, Republic of
-
Exegi Pharma, LLCThe Emmes Company, LLCRecruiting
-
Allena PharmaceuticalsCompleted
-
SanofiCompleted
-
Allena PharmaceuticalsTerminatedChronic Kidney Diseases | Hyperuricemia | GoutUnited States
-
Allena PharmaceuticalsCompletedChronic Kidney Diseases | Hyperuricemia | GoutUnited States
-
Allena PharmaceuticalsCompletedHyperuricemia | GoutUnited States
-
Kansas Joint and Spine InstituteISTO Technologies, Inc.; National Center of Innovation for Biomaterials in...UnknownDegenerative Disc DiseaseUnited States